{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "G2019S has higher activity in kinase activity assays [3][4][5][6][7][8][9] and was recently shown to have an altered ATP K m,app [8].",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that G2019S has higher kinase activity and altered ATP kinetics, which are directly related to the disease mechanism of Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The EC 50 values are also consistent with previously determined IC 50 values from activity assays [8].",
          "judgment": "Yes",
          "reasoning": "The assays used (kinase activity, ATP kinetics) are standard in the field and directly model the disease pathogenesis related to LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "No explicit information provided about controls or replicates.",
          "judgment": "No",
          "reasoning": "The text does not mention whether basic controls (wild-type, null) or replicates were used in the experiments.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The EC 50 values are consistent with previously determined IC 50 values from activity assays [8].",
          "judgment": "Yes",
          "reasoning": "The assay is validated through consistency with previously established IC 50 values, indicating historical acceptance in the field.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting",
        "reasoning": "The assay is historically accepted, but lacks explicit controls and replicates, limiting the strength of the evidence."
      },
      "overall_conclusion": "G2019S shows increased kinase activity and altered ATP kinetics, which are pathogenic indicators. However, the lack of detailed controls reduces the evidence strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "I2020T has lower kinase activity in assays measuring substrate phosphorylation [4,8], whereas it was demonstrated to have either higher activity or unchanged activity in autophosphorylation assays [6,10].",
          "judgment": "Yes",
          "reasoning": "The paper describes I2020T's reduced kinase activity in substrate phosphorylation assays, which is relevant to the disease mechanism of Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The EC 50 values are consistent with previously determined IC 50 values from activity assays [8].",
          "judgment": "Yes",
          "reasoning": "The assays used (substrate phosphorylation, autophosphorylation) are standard and model the disease pathogenesis related to LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "No explicit information provided about controls or replicates.",
          "judgment": "No",
          "reasoning": "The text does not specify whether basic controls or replicates were used in the experiments.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The EC 50 values are consistent with previously determined IC 50 values from activity assays [8].",
          "judgment": "Yes",
          "reasoning": "The assay is validated through consistency with previously established IC 50 values, indicating historical acceptance in the field.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting",
        "reasoning": "The assay is historically accepted, but lacks explicit controls and replicates, limiting the strength of the evidence."
      },
      "overall_conclusion": "I2020T exhibits reduced kinase activity in substrate phosphorylation assays, suggesting benign effects. However, the lack of detailed controls reduces the evidence strength to supporting."
    }
  ]
}